|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
|
17060676 |
2006 |
|
Cardio-facio-cutaneous syndrome
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
|
18042262 |
2008 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
|
23429431 |
2013 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
|
22855150 |
2012 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival.
|
24455489 |
2014 |
|
Cardio-facio-cutaneous syndrome
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
|
16439621 |
2006 |
|
Cardio-facio-cutaneous syndrome
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.
|
19206169 |
2009 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
|
19042984 |
2008 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.
|
24996433 |
2014 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
|
25373533 |
2015 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
|
23263490 |
2013 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
|
22138009 |
2011 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.
|
23852704 |
2014 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Multitarget stool DNA testing for colorectal-cancer screening.
|
25006736 |
2014 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.
|
12198537 |
2002 |
|
Cardio-facio-cutaneous syndrome
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
|
16474404 |
2006 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF.
|
21917714 |
2011 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
|
23012255 |
2012 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
The patients with BRAF K601E- and T599_V600insAGA-mutated tumors had similar clinicopathologic features to those with BRAF V600E-mutated tumors.
|
29037218 |
2017 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
We confirmed the presence of RAS mutations and BRAF K601E mutation in benign, borderline, and malignant follicular-patterned tumors.
|
29723601 |
2018 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
Cytology was consistent with "follicular neoplasia" (negative for galectin-3 immunostaining); molecular analysis on the cytology sample detected a K601E mutation in the exon 15 of the BRAF gene.
|
22136270 |
2011 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
Twenty-three percent of patients with V600E- and 43% of patients with K601E-mutant melanomas presented with nodal disease at diagnosis compared to just 14% of patients with BRAF wild-type tumors (P = 0.001 and 0.006, respectively).
|
26643848 |
2016 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
This technique, together with an earlier described real-time test specific for V600E and K601E will be useful for research and molecular diagnostic laboratories involved in the study of BRAF-related neoplasia.
|
20186005 |
2010 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
The tumor was found to be BRAF mutation positive (K601E).
|
20718682 |
2010 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
All cases positive for the BRAF(K601E) mutation were reviewed to confirm histopathologic diagnosis and establish tumor variant, and clinical charts were reviewed to obtain clinical characteristics and follow-up information.
|
26422023 |
2016 |